

Amyloidosis Therapeutics-Europe Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/AC9ED59A930MEN.html>

Date: February 2018

Pages: 149

Price: US\$ 3,480.00 (Single User License)

ID: AC9ED59A930MEN

Abstracts

Report Summary

Amyloidosis Therapeutics-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Amyloidosis Therapeutics industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole Europe and Regional Market Size of Amyloidosis Therapeutics 2013-2017, and development forecast 2018-2023

Main market players of Amyloidosis Therapeutics in Europe, with company and product introduction, position in the Amyloidosis Therapeutics market

Market status and development trend of Amyloidosis Therapeutics by types and applications

Cost and profit status of Amyloidosis Therapeutics, and marketing status

Market growth drivers and challenges

The report segments the Europe Amyloidosis Therapeutics market as:

Europe Amyloidosis Therapeutics Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Germany

United Kingdom

France

Italy

Spain
Benelux
Russia

Europe Amyloidosis Therapeutics Market: Product Type Segment Analysis
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

AG-10
ALN-ANG
ALN-TTRsc02
CAEL-101
canakinumab
Others

Europe Amyloidosis Therapeutics Market: Application Segment Analysis (Consumption
Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

AL amyloidosis
AA amyloidoses
ATTR amyloidoses
Others

Europe Amyloidosis Therapeutics Market: Players Segment Analysis (Company and
Product introduction, Amyloidosis Therapeutics Sales Volume, Revenue, Price and
Gross Margin):

Pfizer Inc.
ProteoTech, Inc.
Alnylam Pharmaceuticals, Inc.
Arcturus Therapeutics, Inc
Bellus Health Inc.
Bsim2
Celgene Corporation
Millennium Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc.
GlaxoSmithKline Plc
Isis Pharmaceuticals, Inc.
Prothena Corporation Plc
SOM Innovation Biotech SL

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF AMYLOIDOSIS THERAPEUTICS

- 1.1 Definition of Amyloidosis Therapeutics in This Report
- 1.2 Commercial Types of Amyloidosis Therapeutics
 - 1.2.1 AG-10
 - 1.2.2 ALN-ANG
 - 1.2.3 ALN-TTRsc02
 - 1.2.4 CAEL-101
 - 1.2.5 canakinumab
 - 1.2.6 Others
- 1.3 Downstream Application of Amyloidosis Therapeutics
 - 1.3.1 AL amyloidosis
 - 1.3.2 AA amyloidoses
 - 1.3.3 ATTR amyloidoses
 - 1.3.4 Others
- 1.4 Development History of Amyloidosis Therapeutics
- 1.5 Market Status and Trend of Amyloidosis Therapeutics 2013-2023
 - 1.5.1 Europe Amyloidosis Therapeutics Market Status and Trend 2013-2023
 - 1.5.2 Regional Amyloidosis Therapeutics Market Status and Trend 2013-2023

CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Amyloidosis Therapeutics in Europe 2013-2017
- 2.2 Consumption Market of Amyloidosis Therapeutics in Europe by Regions
 - 2.2.1 Consumption Volume of Amyloidosis Therapeutics in Europe by Regions
 - 2.2.2 Revenue of Amyloidosis Therapeutics in Europe by Regions
- 2.3 Market Analysis of Amyloidosis Therapeutics in Europe by Regions
 - 2.3.1 Market Analysis of Amyloidosis Therapeutics in Germany 2013-2017
 - 2.3.2 Market Analysis of Amyloidosis Therapeutics in United Kingdom 2013-2017
 - 2.3.3 Market Analysis of Amyloidosis Therapeutics in France 2013-2017
 - 2.3.4 Market Analysis of Amyloidosis Therapeutics in Italy 2013-2017
 - 2.3.5 Market Analysis of Amyloidosis Therapeutics in Spain 2013-2017
 - 2.3.6 Market Analysis of Amyloidosis Therapeutics in Benelux 2013-2017
 - 2.3.7 Market Analysis of Amyloidosis Therapeutics in Russia 2013-2017
- 2.4 Market Development Forecast of Amyloidosis Therapeutics in Europe 2018-2023
 - 2.4.1 Market Development Forecast of Amyloidosis Therapeutics in Europe 2018-2023
 - 2.4.2 Market Development Forecast of Amyloidosis Therapeutics by Regions

2018-2023

CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES

3.1 Whole Europe Market Status by Types

3.1.1 Consumption Volume of Amyloidosis Therapeutics in Europe by Types

3.1.2 Revenue of Amyloidosis Therapeutics in Europe by Types

3.2 Europe Market Status by Types in Major Countries

3.2.1 Market Status by Types in Germany

3.2.2 Market Status by Types in United Kingdom

3.2.3 Market Status by Types in France

3.2.4 Market Status by Types in Italy

3.2.5 Market Status by Types in Spain

3.2.6 Market Status by Types in Benelux

3.2.7 Market Status by Types in Russia

3.3 Market Forecast of Amyloidosis Therapeutics in Europe by Types

CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Amyloidosis Therapeutics in Europe by Downstream Industry

4.2 Demand Volume of Amyloidosis Therapeutics by Downstream Industry in Major Countries

4.2.1 Demand Volume of Amyloidosis Therapeutics by Downstream Industry in Germany

4.2.2 Demand Volume of Amyloidosis Therapeutics by Downstream Industry in United Kingdom

4.2.3 Demand Volume of Amyloidosis Therapeutics by Downstream Industry in France

4.2.4 Demand Volume of Amyloidosis Therapeutics by Downstream Industry in Italy

4.2.5 Demand Volume of Amyloidosis Therapeutics by Downstream Industry in Spain

4.2.6 Demand Volume of Amyloidosis Therapeutics by Downstream Industry in Benelux

4.2.7 Demand Volume of Amyloidosis Therapeutics by Downstream Industry in Russia

4.3 Market Forecast of Amyloidosis Therapeutics in Europe by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF AMYLOIDOSIS THERAPEUTICS

5.1 Europe Economy Situation and Trend Overview

5.2 Amyloidosis Therapeutics Downstream Industry Situation and Trend Overview

CHAPTER 6 AMYLOIDOSIS THERAPEUTICS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE

6.1 Sales Volume of Amyloidosis Therapeutics in Europe by Major Players

6.2 Revenue of Amyloidosis Therapeutics in Europe by Major Players

6.3 Basic Information of Amyloidosis Therapeutics by Major Players

6.3.1 Headquarters Location and Established Time of Amyloidosis Therapeutics Major Players

6.3.2 Employees and Revenue Level of Amyloidosis Therapeutics Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 AMYLOIDOSIS THERAPEUTICS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Pfizer Inc.

7.1.1 Company profile

7.1.2 Representative Amyloidosis Therapeutics Product

7.1.3 Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin of Pfizer Inc.

7.2 ProteoTech, Inc.

7.2.1 Company profile

7.2.2 Representative Amyloidosis Therapeutics Product

7.2.3 Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin of ProteoTech, Inc.

7.3 Alnylam Pharmaceuticals, Inc.

7.3.1 Company profile

7.3.2 Representative Amyloidosis Therapeutics Product

7.3.3 Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin of Alnylam Pharmaceuticals, Inc.

7.4 Arcturus Therapeutics, Inc

7.4.1 Company profile

7.4.2 Representative Amyloidosis Therapeutics Product

7.4.3 Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin of Arcturus Therapeutics, Inc

7.5 Bellus Health Inc.

- 7.5.1 Company profile
- 7.5.2 Representative Amyloidosis Therapeutics Product
- 7.5.3 Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin of Bellus Health Inc.
- 7.6 Bsim2
 - 7.6.1 Company profile
 - 7.6.2 Representative Amyloidosis Therapeutics Product
 - 7.6.3 Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin of Bsim2
- 7.7 Celgene Corporation
 - 7.7.1 Company profile
 - 7.7.2 Representative Amyloidosis Therapeutics Product
 - 7.7.3 Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin of Celgene Corporation
- 7.8 Millennium Pharmaceuticals, Inc.
 - 7.8.1 Company profile
 - 7.8.2 Representative Amyloidosis Therapeutics Product
 - 7.8.3 Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin of Millennium Pharmaceuticals, Inc.
- 7.9 Onyx Pharmaceuticals, Inc.
 - 7.9.1 Company profile
 - 7.9.2 Representative Amyloidosis Therapeutics Product
 - 7.9.3 Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin of Onyx Pharmaceuticals, Inc.
- 7.10 GlaxoSmithKline Plc
 - 7.10.1 Company profile
 - 7.10.2 Representative Amyloidosis Therapeutics Product
 - 7.10.3 Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin of GlaxoSmithKline Plc
- 7.11 Isis Pharmaceuticals, Inc.
 - 7.11.1 Company profile
 - 7.11.2 Representative Amyloidosis Therapeutics Product
 - 7.11.3 Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin of Isis Pharmaceuticals, Inc.
- 7.12 Prothena Corporation Plc
 - 7.12.1 Company profile
 - 7.12.2 Representative Amyloidosis Therapeutics Product
 - 7.12.3 Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin of Prothena Corporation Plc
- 7.13 SOM Innovation Biotech SL

- 7.13.1 Company profile
- 7.13.2 Representative Amyloidosis Therapeutics Product
- 7.13.3 Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin of SOM Innovation Biotech SL

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF AMYLOIDOSIS THERAPEUTICS

- 8.1 Industry Chain of Amyloidosis Therapeutics
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF AMYLOIDOSIS THERAPEUTICS

- 9.1 Cost Structure Analysis of Amyloidosis Therapeutics
- 9.2 Raw Materials Cost Analysis of Amyloidosis Therapeutics
- 9.3 Labor Cost Analysis of Amyloidosis Therapeutics
- 9.4 Manufacturing Expenses Analysis of Amyloidosis Therapeutics

CHAPTER 10 MARKETING STATUS ANALYSIS OF AMYLOIDOSIS THERAPEUTICS

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Reference

I would like to order

Product name: Amyloidosis Therapeutics-Europe Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/AC9ED59A930MEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AC9ED59A930MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970